Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024. ...
The Uromigos: ESMO
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, discuss research and news from ESMO.
Advertisement
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
Fresh off the Presidential session address, Tom discusses his data with Petros commenting.
Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC.
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotin + pembrolizumab in bladder cancer.
Silke Gillessen joins us to discuss her Presidential session from ESMO 2024.
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC.
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC.
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
Dr. Gillessen joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024.
Silke Gillessen, MD, PhD recaps some of the kidney, bladder, and prostate cancer data from this year's ESMO meeting.
Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer.
Xinan Sheng, MD, joins the podcast to discuss the RENOTORCH trial on toripalimab plus axitinib for advanced RCC.
Michiel Van der Heijdan, MD, PhD, discusses EV-302 and CheckMate-901 on EV plus pembrolizumab and nivolumab plus ipilimumab.
Yohann Loriot, MD, PhD, gives an update on the use of erdafitinib within the THOR randomized phase 3 trial.
Dr. Lisa Pickering discusses 3 different renal cancer abstracts that were presented at ESMO 2023.
Dr. Brad McGregor discusses the DAD trial on sacituzumab govitecan plus enfortumab vedotin for the treatment of mUC.
Louise Emmett discusses the phase 2 ENZA-p trial presented at ESMO 2023 on enzalutamide and 177Lu-PSMA-617 for mCRPC.
Silke Gillessen, MD, PhD joins us to discuss the upcoming ESMO conference and panels of interest to look out for.
ESMO 2022: Enfortumab Vedotin Plus Pembrolizumab Versus Pembrolizumab Alone for Urothelial Carcinoma
Peter O'Donnell describes the randomized phase 2 study on enfortumab vedotin and pembrolizumab against pembrolizumab alone.Nizar Tannir describes this randomized phase 3 study on bempegaldesleukin plus nivolumab as presented at ESMO.
The phase III PRESTO study examined the effects of androgen suppressants on biochemically relapsed prostate cancer.
Axel Bex summarizes the ipi/nivo, pembro and atezo studies that were presented at ESMO 2022.
Mohamad Allaf gives a recap of the open-label PROSPER study on neoadjuvant nivolumab in RCC.
Chris Sweeney joins to talk about potential highlights to be presented at ESMO 2022.
Dr. Naveed Vasudev discusses IPI dosing and findings from the PRISM study.
Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom.
Dr. Cora Sternber discusses AMG 160 and the future of immunotherapy in CRPC.
Chris Sweeney discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC, a positive R3 trial in the ESMO plenary session.
Dr. Richard Cathomas goes into the detail of chemo immune combinations and what to do next.
Dr. Toni Choueiri and the Uromigos attempt to put the data into context with the other available combinations.
Matt Galsky tries to get to the bottom of whether these data has made any difference in treatment and future plans.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.